Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 198

1.

Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials Network.

Graham BS, Gorse GJ, Schwartz DH, Keefer MC, McElrath MJ, Matthews TJ, Wright PF, Belshe RB, Clements ML, Dolin R, et al.

J Infect Dis. 1994 Oct;170(4):782-6.

PMID:
7930718
2.

Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. The AIDS Vaccine Clinical Trials Network.

Graham BS, Belshe RB, Clements ML, Dolin R, Corey L, Wright PF, Gorse GJ, Midthun K, Keefer MC, Roberts NJ Jr, et al.

J Infect Dis. 1992 Aug;166(2):244-52.

PMID:
1353102
3.

Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network.

Graham BS, Matthews TJ, Belshe RB, Clements ML, Dolin R, Wright PF, Gorse GJ, Schwartz DH, Keefer MC, Bolognesi DP, et al.

J Infect Dis. 1993 Mar;167(3):533-7.

PMID:
8095059
4.
5.
6.

A vaccinia-gp160-based vaccine but not a gp160 protein vaccine elicits anti-gp160 cytotoxic T lymphocytes in some HIV-1 seronegative vaccinees.

Perales MA, Schwartz DH, Fabry JA, Lieberman J.

J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Sep 1;10(1):27-35.

PMID:
7648281
7.

Immune responses elicited by recombinant vaccinia-human immunodeficiency virus (HIV) envelope and HIV envelope protein: analysis of the durability of responses and effect of repeated boosting.

McElrath MJ, Corey L, Berger D, Hoffman MC, Klucking S, Dragavon J, Peterson E, Greenberg PD.

J Infect Dis. 1994 Jan;169(1):41-7.

PMID:
8277196
8.

Technology evaluation: HIVAC-1e.

Zheng R.

Curr Opin Mol Ther. 1999 Feb;1(1):121-5. Review.

PMID:
11249677
9.
10.

Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein.

Cooney EL, Collier AC, Greenberg PD, Coombs RW, Zarling J, Arditti DE, Hoffman MC, Hu SL, Corey L.

Lancet. 1991 Mar 9;337(8741):567-72.

PMID:
1671940
11.

Adenovirus-human immunodeficiency virus (HIV) envelope recombinant vaccines elicit high-titered HIV-neutralizing antibodies in the dog model.

Natuk RJ, Chanda PK, Lubeck MD, Davis AR, Wilhelm J, Hjorth R, Wade MS, Bhat BM, Mizutani S, Lee S, et al.

Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7777-81.

12.
14.

The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network.

Dolin R, Graham BS, Greenberg SB, Tacket CO, Belshe RB, Midthun K, Clements ML, Gorse GJ, Horgan BW, Atmar RL, et al.

Ann Intern Med. 1991 Jan 15;114(2):119-27.

PMID:
1984386
15.
16.
17.
18.

Response of monkeys to vaccination with recombinant vaccinia virus which coexpress HIV gp160 and human interleukin-2.

Ruby J, Brinkman C, Jones S, Ramshaw I.

Immunol Cell Biol. 1990 Apr;68 ( Pt 2):113-7.

19.

Human studies in the development of human immunodeficiency virus vaccines.

Dolin R.

J Infect Dis. 1995 Nov;172(5):1175-83. Review.

PMID:
7594651
20.

Supplemental Content

Support Center